Your Directors take pleasure in presenting the Thirtieth Annual Report
and Company's Audited Financial Statements for the financial year ended March 31, 2022
(‘FY2021-22').

FINANCIAL RESULTS

  

    

    

    

    

    
(Rs in Million)
  
  

    

    
Standalone
    
Consolidated
  
  

    

    
Year ended March 31, 2022
    
*Year ended March 31, 2021
    
Year ended March 31, 2022
    
Year ended March 31, 2021
  
  

    
Revenue from operations
    
155,859.8
    
141,160.5
    
386,544.9
    
334,981.4
  
  

    
Profit before exceptional item and tax
    
21,273.9
    
9,451.3
    
90,481.4
    
71,055.1
  
  

    
Exceptional Item
    
18,205.3
    
895.6
    
45,668.2
    
43,061.4
  
  

    
Profit before tax but after exceptional item
    
3,068.6
    
8,555.7
    
44,813.2
    
27,993.7
  
  

    
Profit/(Loss) after tax
    
(999.9)
    
8,424.0
    
34,058.2
    
22,846.8
  
  

    
Opening balance in Retained Earnings
    
159,645.5
    
140,052.7
    
365,980.9
    
353,200.5
  
  

    
Closing balance in Retained Earnings
    
136,120.8
    
159,645.5
    
376,456.5
    
365,980.9
  

*Refer Note 54(12) of Standalone Financial Statements

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF
THE COMPANY, BETWEEN THE END OF THE FINANCIAL YEAR AND THE DATE OF THIS REPORT
There have been no material changes and commitments affecting the
financial position of the Company, between the end of the financial year and the date of
this report.

CONSOLIDATED ACCOUNTS
The consolidated financial statements for the year ended March 31,
2022, have been prepared in accordance with Indian Accounting Standards (Ind AS) notified
under the Companies (Indian Accounting Standards) Rules, 2015.

DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to the requirements under Section 134(5) read with Section
134(3)(c) of the Companies Act, 2013 (‘Act') with respect to Directors'
Responsibility Statement, it is hereby confirmed that:
a) in the preparation of the annual accounts for the financial year
ended March 31, 2022, the applicable accounting standards have been followed and there are
no material departures from the same;
b) the Directors have selected such accounting policies and applied
them consistently and made judgments and estimates that are reasonable and prudent so as
to give a true and fair view of the state of affairs of the Company as at March 31, 2022,
and of the loss of the Company for the year ended on that date;
c) the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of the Act
for safeguarding the assets of the Company and for preventing and detecting fraud and
other irregularities;
d) the Directors have prepared the annual accounts on a going concern
basis;
e) the Directors have laid down internal financial controls to be
followed by the Company and that such internal financial controls are adequate and were
operating effectively; and
f) the Directors have devised proper systems to ensure compliance with
the provisions of all applicable laws and that such systems were adequate and operating
effectively.

MANAGEMENT DISCUSSION AND ANALYSIS
The Management Discussion and Analysis as prescribed under Part B of
Schedule V read with Regulation 34(3) of the Listing Regulations is provided in a separate
section and forms part of this Report.

DIVIDEND
During the year under review, your Directors at their meeting held on
January 31, 2022 declared an interim dividend of Rs 7/- (Rupees Seven only) per equity
share of Rs 1/- (Rupee One only) each [previous year Rs 5.50/- (Rupees Five and Paisa
Fifty only) per equity share of Rs 1/- (Rupee One only) each] for the year ended March 31,
2022. The interim dividend was paid on February 18, 2022 to those shareholders who held
shares as on February 10, 2022, being the record date.
In addition to above, your Directors have recommended a final dividend
of Rs 3/- (Rupees Three only) per equity share of Rs 1/- (Rupee One only) each [previous
year Rs 2/- (Rupees Two only) per equity share of Rs 1/- (Rupee One only) each] for the
year ended March 31, 2022, subject to the approval of the equity shareholders at the
ensuing 30th Annual General Meeting of the Company.
The total dividend payout for FY2021-22 would be Rs 10/- (Rupees Ten
only) per equity share of Rs 1/- (Rupees One only) each [previous year Rs 7.50/- (Rupees
Seven and Paisa Fifty only) per equity share of Rs 1/- (Rupee One only) each].
The dividend payout is in accordance with the Company's Dividend
Distribution Policy. The policy is available on the website of the Company and can be
accessed through the web link: https://sunpharma.com/policies/.

TRANSFER TO RESERVES
The Directors do not propose any transfer to reserve.

CHANGES IN CAPITAL STRUCTURE
During the year under review there was no change in the Capital
Structure of the Company.

CREDIT RATING
ICRA Ltd. has reaffirmed the highest credit rating of ‘[ICRA]
A1+'/ ‘[ICRA] AAA (Stable)' for the bank facilities, short term/ long term borrowings
and commercial paper programs of the Company.
Further, CRISIL Ltd. has also reaffirmed the highest credit rating of
‘CRISIL A1+ and CRISIL AAA/Stable' for short tern & long term bank facilities and
commercial paper programs of the Company.

SUBSIDIARIES/ JOINT VENTURES/ ASSOCIATES
The statement containing the salient features of the Financial
Statements of the Company's subsidiaries/ joint ventures/ associates is given in Form AOC
- 1, provided in Notes to the Consolidated Financial Statements, forming part of the
Annual Report.
The highlights of performance of subsidiaries, joint ventures and
associates and their contribution to the overall performance of the Company during the
financial year under review is given under Annexure ‘A' to the Consolidated Financial
Statements forming part of the Annual Report.
Details pertaining to entities that became subsidiaries/ joint
ventures/ associates and those that ceased to be the subsidiaries/ joint ventures/
associates of the Company during the year under review are provided in the notes to the
Consolidated Financial Statements, forming part of the Annual Report.

SCHEME OF AMALGAMATION
1. National Company Law Tribunal (NCLT) vide its Order dated August 31,
2021, sanctioned the Scheme of Amalgamation and Merger of Sun Pharma Global FZE
("Transferor Company"), an indirect wholly owned subsidiary of the Company with
Sun Pharmaceutical Industries Limited ("Company") pursuant to Section 234 read
with Sections 230 to 232 of the Companies Act, 2013 and the relevant rules and regulations
made
thereunder. The Scheme is effective from October 1, 2021 with appointed
date as January 1, 2020 and Sun Pharma Global FZE has been merged with the Company.
2. The Board of Directors of the Company at its meeting held on May 30,
2022 has approved the Scheme of Amalgamation of Sun Pharmaceutical Medicare Limited, Green
Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone
Multitrade Private Limited, Skisen Labs Private Limited, Wholly-owned Subsidiaries of the
Company with the Company.

DIRECTORS AND KEY MANAGERIAL PERSONNEL
During the year, following were the changes in Directors/
Key Managerial Personnel:
1. Dr. Pawan Goenka has been appointed as the Independent Director
w.e.f. May 21, 2021 for a period of five years by the shareholders at the 29th Annual
General Meeting.
2. Ms. Rama Bijapurkar has been appointed as the Independent Director
w.e.f. May 21, 2021 for a period of five years by the shareholders at the 29th Annual
General Meeting.
3. Ms. Rekha Sethi retired and ceased to be the Independent Director
w.e.f. August 31, 2021 i.e. upon conclusion of the 29th Annual General Meeting.
4. Mr. Vivek Chaand Sehgal resigned as the Independent Director with
effect from September 1, 2021.
5. Mr. Sunil Ajmera resigned from the position of Company Secretary and
Compliance Officer w.e.f. the close of business hours of January 31, 2022.
6. Mr. Anoop Deshpande has been appointed as Company Secretary and
Compliance Officer effective from closure of business hours of January 31, 2022.
After the year end and up to the date of the Report,
following were the changes:
1. The Board of Directors at its meeting held on May
30, 2022, on the recommendation by Nomination and Remuneration
Committee, has approved the re-appointment and remuneration of Mr. Dilip Shanghvi as
Managing Director for further period of five years with effect from i.e. April 1, 2023 to
March
31, 2028, subject to approval of the shareholders at the 30th Annual
General Meeting.
2. The Board of Directors at its meeting held on May 30, 2022, on the
recommendation by Nomination and Remuneration Committee, has approved the re-appointment
of Mr. Gautam Doshi as Independent Director for further period of five years with effect
from
i.e. May 25, 2023 to May 24, 2028, subject to approval of the
shareholders at the 30th Annual General Meeting.
Mr. Sailesh T. Desai and Mr. Israel Makov Directors of the Company,
retire by rotation at the 30th Annual General Meeting.
The necessary disclosures required under the Companies Act, 2013 and
the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and
Secretarial Standards-2 on General Meetings issued by the Institute of Company Secretaries
of India, for the above-mentioned appointments/ re-appointment are provided in the 30th
Annual General Meeting Notice of the Company.

DECLARATION BY INDEPENDENT DIRECTORS
The Company has received declarations from all the Independent
Directors confirming that they meet the criteria of independence as prescribed under
Section 149(6) of the Act and under Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 ("Listing
Regulations").
In the opinion of the Board, the Independent Directors fulfil the
conditions specified under the Act and Listing Regulations and are independent of the
management. The Board skill/ expertise/ competencies matrix of all the Directors,
including the Independent Directors is provided in the Corporate Governance Report forming
part of this Annual Report.

FAMILIARISATION PROGRAMME FOR THE INDEPENDENT DIRECTORS
In compliance with the requirements of Regulation 25(7) of the Listing
Regulations, the Company has put in place a Familiarisation Programme for the Independent
Directors to familiarise them with the Company, their roles, rights, responsibilities in
the Company, nature of the industry in which the Company operates, business model etc. The
details of the Familiarisation Programme conducted are available on the website of the
Company: https://sunpharma.com/policies/.

EVALUATION OF PERFORMANCE OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL
DIRECTORS
During the year, annual performance evaluation of the Board and
Committees of the Board, individual Directors including the Chairman of the Company, was
carried out as per the criteria and process approved by Nomination and Remuneration
Committee, which is in line with the SEBI Guidance Note on Board Evaluation.
The Chairman and other members of the Board discussed upon the
performance evaluation outcome and concluded that they were satisfied with the overall
performance of the Board and Committees of the Board and Directors individually. The Board
also assessed the fulfillment of the independence criteria as specified in Listing
Regulations, by the Independent Directors of the Company and their independence from the
management.
The performance evaluation of the Non-Independent Directors including
the Chairman of the Company and performance of the Board as a whole was discussed at the
separate meeting of the Independent Directors.

REMUNERATION POLICY FOR DIRECTORS, KEY MANAGERIAL PERSONNEL AND OTHER
EMPLOYEES AND CRITERIA FOR APPOINTMENT OF DIRECTORS
For the purpose of selection of any Director, the Nomination and
Remuneration Committee identifies persons of integrity who possess relevant expertise,
experience and leadership qualities required for the position. The Committee also ensures
that the incumbent fulfils such criteria with regard to qualifications, positive
attributes, independence, age and other criteria as laid down under the Act, Listing
Regulations or other applicable laws and the diversity attributes as per the Board
Diversity Policy of the Company. The Board has, on the recommendation of the Nomination
and Remuneration Committee framed a Policy on remuneration of Directors, Key Managerial
Personnel and other Employees.
The salient features of the Remuneration Policy of the Company are as
under:
A. Guiding Principles for remuneration: The Company shall remunerate
all its personnel reasonably and sufficiently as per industry benchmarks and standards.
The remuneration shall be commensurate to retain and motivate the human resources of the
Company. The compensation package will, inter alia, take into account the experience of
the personnel, the knowledge & skill required including complexity of his job, work
duration and risks associated with the work, and attitude of the employee like positive
outlook, team work, loyalty etc.
B. Components of Remuneration: The following will be the various
remuneration components which may be paid to the personnel of the Company based on the
designation and class of the personnel.
a) Fixed compensation: The fixed salaries of the Company's personnel
shall be competitive and based on the individual personnel's responsibilities and
performance.
b) Variable compensation: The personnel of the Company may be paid
remuneration by way of variable salaries based on their performance evaluation. Such
variable salaries should be based on the performance of the individual against his short
and long term performance objectives and the performance of the Company.
c) Share based payments: The Board may, on the recommendation of the
Nomination and Remuneration Committee, issue to certain class of personnel a share and
share price related incentive program.
d) Non-monetary benefits: Senior management personnel of the Company
may, on a case to case basis, be awarded customary non-monetary benefits such as
discounted salary advance/ credit facility, rent free accommodation, Company cars with or
without chauffer, share and share price related incentive, reimbursement of electricity
and telephone bills etc.
e) Gratuity/group insurance: Personnel may also be awarded to group
insurance and other key man insurance protection. Further as required by the law necessary
gratuity shall be paid to the personnel.
f) Commission: The directors may be paid commission if approved by the
shareholders.
The shareholders may authorise the Board to declare commission to be
paid to any director of the Board.
The complete Policy as approved by the Board is available on the
website of the Company and can be accessed through the web link:
https://sunpharma.com/policies/.
Information as per Section 197 (12) of the Act read with Rule 5(1) of
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is
provided in ‘Annexure - A' to this Report. Further, the information pertaining to
Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014, pertaining to the names and other particulars of employees is
available for inspection at the Registered office of the Company during business hours and
pursuant to the second proviso to Section 136(1) of the Act, the Report and the accounts
are being sent to the members excluding this. Any shareholder interested in obtaining a
copy of the same may write to the Company Secretary & Compliance Officer either at the
Registered/ Corporate Office address or by email to secretarial@sunpharma.com.

BOARD MEETINGS
The Board of Directors of the Company met 5 (Five) times during the
year under review. The dates of the Board meeting and the attendance of the Directors at
the said meetings are provided in detail in the Corporate Governance Report, which forms a
part of this Report.

COMMITTEES OF THE BOARD
As on March 31, 2022, the Board has 6 (six) Committees. Audit
Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee,
Risk Management Committee, Corporate Social Responsibility Committee and Corporate
Governance & Ethics Committee.
The details pertaining to the meetings and composition of the
Committees of the Board are included in the Corporate Governance Report, which forms part
of this Report.

RELATED PARTY TRANSACTIONS
The policy on Related Party Transactions as approved by the Board is
available on the website of the Company and can be accessed through the web link:
https://www. sunpharma.com/policies. All contracts/ arrangements/ transactions entered by
the Company during the year under review with the related parties were in the ordinary
course of business and on an arm's length basis.
As required under Section 134(3)(h) of the Act, details of transactions
entered with related parties under the Act exceeding ten percent of the annual
consolidated turnover as per the last audited financial statements are given in Form AOC-2
provided as ‘Annexure - B' to this Report.

INTERNAL CONTROLS
The Company believes that internal controls are the prerequisite of
governance and that action emanating out of agreed business plans should be exercised
within a framework of checks and balances. The Company has a well-established internal
controls framework, which is designed to continuously assess the adequacy, effectiveness
and efficiency of internal controls. The management is committed to ensuring an effective
internal controls environment, commensurate with the size and complexity of the business,
which provides an assurance on compliance with internal policies, applicable laws,
regulations, ensures accuracy of records, promotes operational efficiency, protects
resources and assets and overall minimize the risks.

INTERNAL FINANCIAL CONTROLS
The Company has a well-established internal financial controls
framework, which is designed to continuously assess the adequacy, effectiveness and
efficiency of internal financial controls. The management is committed to ensuring an
effective internal financial controls environment, commensurate with the size and
complexity of the business, which provides an assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles.

GLOBAL INTERNAL AUDIT
An independent and empowered Global Internal Audit Function (GIA) at
the corporate level with support from a Big 4/ equally reputed audit firms, wherever
required, carries out risk-based audits. GIA audits all businesses to ensure that business
process controls are adequate and are functioning effectively. These reviews include
financial, operational and compliance controls and risk mitigation plans. The Company's
operating management closely monitors the internal control environment and ensures that
the audit recommendations are effectively implemented.
The Audit Committee of the Board monitors performance of the Internal
Audit Function, periodically reviews key findings and provides strategic guidance.
GIA's functioning is governed by the Audit Charter, duly approved by
the Audit Committee of the Board, which stipulates matters contributing to the proper and
effective conduct of the audit.

RISK MANAGEMENT
The Board of Directors has constituted a Risk Management Committee
which is entrusted with the responsibility of overseeing various organizational risks. The
Risk Management Committee also assesses the adequacy of mitigation plans to address such
risks. The Corporate Governance Report, which forms part of this report, contains the
details of Risk Management Committee of the Company. An overarching Risk Management Policy
which was approved by the Board is in place.
The Company has developed and implemented an integrated Enterprise Risk
Management (ERM) Framework through which it identifies, monitors, mitigates and reports,
key risks that impact the Company's ability to meet its strategic objectives.
The ERM team engages with all Function heads to identify internal and
external events that may have an adverse impact on the achievement of Company's objectives
and periodically monitors changes in both internal and external environment leading to
emergence of a new threat/risk. These risks are captured in a risk register with all the
relevant information such as risk area, risk description, risk rating, root cause and
mitigation plans, action items etc. The risk register is refreshed semi-annually. Risks
are categorised into various categories viz. Strategic, Financial, Operational,
Compliance, Cyber, Geo-Political etc. During FY 21-22, the focus was on reviewing
effectiveness of actions taken to mitigate the identified risks as well as to identify the
new risks and associated risk-mitigation plans, emerging out of constantly changing
geo-political situation across the globe.
Outcome of Enterprise Risk Assessments covering Company's various
businesses and functions, are one of the key input for the annual internal audit plan.

WHISTLE BLOWER POLICY/ VIGIL MECHANISM
To create enduring value for all stakeholders and ensure the highest
level of honesty, integrity and ethical behaviour in all its operations, the Company has
adopted a ‘Global Whistle Blower Policy' for Sun Pharmaceutical Industries Limited
and all its subsidiaries, in addition to the existing Global Code of Conduct that governs
the actions of its employees. Further details on vigil mechanism of the Company are
provided in the Corporate Governance Report, forming part of this Report.

AUDITORS Statutory Auditors
S R B C & Co LLP, Chartered Accountants, (Firm's Regn.
No. 324982E/ E300003), were appointed as the Statutory Auditors of the
Company for a period of 5 (five) years at the 25th Annual General Meeting of the Company
to hold office till the conclusion of the 30th Annual General Meeting of the Company.
In terms of provisions of sections 139 read with the Companies (Audit
and Auditors) Rules, 2014.S R B C & Co LLP, Chartered Accountants are eligible to be
re-appointed for a further term of 5 (five) years.
The Company has received the consent, certificate of eligibility and a
certificate issued by the Peer Review Board of the Institute of Chartered Accountants of
India (ICAI) in accordance with Sections 139, 141 and other applicable provisions of the
Act and Rules issued thereunder and as required under the Listing Regulations, from S R B
C & Co LLP, chartered Accountants.
Accordingly, the Board of Directors at its meeting held on May 30,
2022, based on the recommendation of the Audit Committee have approved and recommended the
reappointment of S R B C & Co LLP, Chartered Accountants, (Firm's Regn. No. 324982E/
E300003), as the Statutory Auditors, for a further period of 5 (five) years i.e. from the
conclusion of the 30th Annual General Meeting till the conclusion of the 35th Annual
General Meeting of the Company, for approval of the Shareholders of the Company at the
ensuing 30th Annual General Meeting.
The Auditor's Report for the financial year ended March 31, 2022, has
been issued with an unmodified opinion, by the Statutory Auditors.

Secretarial Auditor
The Board had appointed KJB & Co. LLP, Practicing Company
Secretaries, to undertake the Secretarial Audit of the Company for the financial year
ended March 31, 2022. The Secretarial Audit Report in the Form No. MR - 3 for the year is
provided as ‘Annexure - C1' to this Report.
The Secretarial Audit Report for the year does not contain any
qualification, reservation or adverse remark.
In accordance with the provision of Regulation 24A of the Listing
Regulations, Secretarial Audit of two material unlisted Indian subsidiaries of the Company
namely, Sun Pharma Laboratories Limited (SPLL) and Sun Pharma Distributors Limited (SPDL),
was undertaken by KJB &
Co. LLP, Practicing Company Secretaries, Mumbai and the Secretarial
Audit Reports issued by them are provided as ‘Annexure - C2' and ‘Annexure - C3'
respectively to this Report. The Secretarial Audit Reports for these material unlisted
Indian subsidiaries do not contain any qualification, reservation or adverse remark.

Cost Auditor
The Board has appointed K D & Co, Cost Accountants, (Firm's
Registration No. 004076) as Cost Auditor of the Company for conducting Cost Audit in
respect of Bulk Drugs & Formulations of your Company for the financial year 2022-23.
The Company is required to maintain Cost Records as specified by the
Central Government under Section 148(1) of the Act and accordingly, such accounts and
records are made and maintained by the Company.

CORPORATE SOCIAL RESPONSIBILITY
In compliance with the requirements of Section 135 of the Act read with
the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Board of Directors
has constituted a Corporate Social Responsibility (CSR) Committee. The details of
membership of the Committee and the meetings held are detailed in the Corporate Governance
Report, forming part of this Report. The CSR Policy of the Company is available on the
website of the Company and can be accessed through the web link:
https://sunpharma.com/policies/.
The annual report on CSR activities containing details of expenditure
incurred by the Company and brief details on the CSR activities are provided in
‘Annexure - D' to this Report.
The Board has accorded its consent to set off the excess amount spent
by the Company on its CSR Activities against the requirement to spend in terms of Section
135 of the Companies Act, 2013 in any subsequent year(s).

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT
The Business Responsibility and Sustainability Report of the Company
for the year ended March 31, 2022, is provided in a separate section and forms part of
this Annual Report and is also made available on the website of the Company at
https://sunpharma.com/investors-annual-reports- presentations/.

HUMAN RESOURCES
FY2021-22 was a very challenging year for everyone. Our 38,000+ strong
global workforce worked relentlessly to ensure medicines continue to reach patients who
rely on us. As lockdowns continued across the world, our teams being part of essential
services, ensured our 43 manufacturing sites, distribution centres, R&D centres and
sales offices worldwide continue to operate. We are grateful to our employees who made
this happen with a safety-first mind set. The top priority for the Human Resource function
was providing a safe work environment to employees globally.
Your Directors would like to take this opportunity to express their
gratitude and appreciation for the passion, dedication and commitment of the employees and
look forward to their continued contribution.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013
Your Company strongly believes in providing a safe and harassment free
workplace for each and every individual working for the Company through various
interventions and practices. It is the continuous endeavour of the Management of the
Company to create and provide an environment to all its employees that is free from
discrimination and harassment including sexual harassment. The Company has adopted a
policy on prevention, prohibition and redressal of sexual harassment at workplace in line
with the provisions of the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 and the Rules made thereunder.
The Company has arranged various interactive awareness workshops in
this regard for the employees at the manufacturing sites, R & D set ups &
corporate office during the year under review. The Company has submitted the Annual
Returns to the local authorities, as required under the above-mentioned Act.
During the financial year ended March 31, 2022, two complaints
pertaining to sexual harassment were received. The complaints were resolved and there are
no complaints pending as at the end of the financial year.
Your Company has complied with provisions relating to the constitution
of Internal Complaints Committee under the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013.

CORPORATE GOVERNANCE REPORT
Report on Corporate Governance and Certificate of the Auditors of the
Company regarding compliance of the conditions of Corporate Governance as stipulated in
Part C of Schedule V of the Listing Regulations, are provided in a separate section and
forms part of this Report.

SECRETARIAL STANDARDS
The Company has complied with the applicable Secretarial Standards as
amended from time to time.

LOANS, GUARANTEES & INVESTMENTS
The particulars of loans, guarantees and investments have been
disclosed in the Financial Statements.

PUBLIC DEPOSITS
The Company has not accepted any deposit from the Public during the
year under review.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO
The information on conservation of energy, technology absorption and
foreign exchange earnings and outgo as stipulated under Section 134(3)(m) of the Act read
with Rule 8 of the Companies (Accounts) Rules, 2014, is provided as ‘Annexure - E' to
this Report.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR
TRIBUNALS
There are no significant and material orders passed by the regulators
or courts or tribunals which impact the going concern status.

ANNUAL RETURN
The Annual Return as required under sub-section (3) of Section 92 of
the Companies Act, 2013 (‘the Act') in form MGT-7 is made available on the website of
the Company and can be accessed at https://sunpharma.com/investors-
annual-reports-presentations.

ACKNOWLEDGEMENTS
Your Directors wish to thank all stakeholders, employees and business
partners, Company's bankers, medical professionals and business associates for their
continued support and valuable cooperation.
The Directors also wish to express their gratitude to investors for the
faith that they continue to repose in the Company.
For and on behalf of the Board of Directors

  

    

    
Dilip Shanghvi
    
Sailesh T. Desai
  
  

    
Place: Mumbai
    
Managing Director
    
Whole-time Director
  
  

    
Date: May 30, 2022
    
(DIN: 00005588)
    
(DIN:00005443)